The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has announced new safety measures for all patients taking antidepressants, requiring clearer information about suicide risk across all age groups and, for the first time, recognizing Post-SSRI Sexual Dysfunction (PSSD) as a potential side effect that can persist after treatment stops. The changes, prompted by patient and family concerns, apply to ten antidepressants including citalopram, escitalopram, duloxetine, fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine, amitriptyline, and nortriptyline. The implications are significant: the MHRA has once again acted before the U.S. Food and Drug Administration, and theCitizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, is now calling on the FDA to issue equivalent warnings.
The history of regulatory divergence is stark. In December 2003, the MHRA became the first regulator to warn that SSRI antidepressants increased suicide and self-harm risk in young people, a move prompted by Dr. David Healy, professor of psychiatry at Bangor University. The FDA had relevant data for decades: a 1985 memo from the manufacturer of fluoxetine reported a suicide rate 5.6 times higher than for older tricyclic antidepressants, and in 1991 CCHR helped secure an FDA advisory committee hearing into antidepressants causing suicidal ideation and violent behavior, though the panel—many with pharmaceutical industry conflicts—dismissed the risks. The FDA eventually added a black-box warning in October 2004, nearly a year after the UK action, but limited it to those 18 and younger, later extended to age 24, leaving the implication that risk ends at 25. Dr. Healy warned in 2009 that antidepressants pose a suicide risk in all age groups, citing elevated relative risks for completed suicide in ages 18–64 based on FDA trial data.
The UK's new measures also address persistent sexual dysfunction, a condition the FDA has not recognized with class-wide labeling. In 2018, Healy and 22 international experts petitioned the FDA to require warnings that these drugs can reduce genital sensitivity—sometimes within 30 minutes of the first dose—with effects that may last for years or indefinitely after discontinuation. The FDA has not acted. Meanwhile, the European Medicines Agency adopted warnings in 2019, and Health Canada followed in 2021. In the UK, healthcare professionals must now discuss both suicide risk and persistent sexual dysfunction when starting, changing, or reviewing antidepressant treatment, and patient information leaflets will feature boxed warnings. "Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions," said Dr. Alison Cave, chief safety officer at the MHRA.
The scale of the U.S. population affected underscores the stakes. According to the IQVia Total Patient Tracker Database for 2020, 45,204,771 Americans were taking antidepressants, including 2,154,118 in the 0–17 age group. CCHR argues that without FDA action, millions of patients are at risk without the full safety disclosures now required in the UK and Europe. The group urges the FDA to align U.S. labeling and patient information with the MHRA's updated measures, providing American patients and families with the same warnings about suicide risk for all ages and persistent sexual dysfunction.
